At the news
? BULLISHIMPACT 7/10 8-K filed Jul 28, 2026 at 07:13 ET
Repligen reported Q2 2026 revenue of $204M (+12% YoY) and adjusted EPS of $0.54, beating consensus by 20.4%. The company raised full-year 2026 guidance for organic revenue growth to 10.5%-13.5% and adjusted EPS to $2.03-$2.09, while also announcing a definitive agreement to acquire BioLife Solutions, a strategic move into cell therapy consumables.
- Q2 2026 revenue $204M, +12% reported and +13% organic YoY
- Adjusted EPS $0.54 vs consensus $0.45 (beat by 20.4%)
- GAAP EPS $0.09 vs $0.26 YoY due to acquisition/amortization costs
- Raised FY26 guidance: organic growth 10.5%-13.5%, adjusted EPS $2.03-$2.09
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access